[Efficacy of terminal warm blood cardioplegia in combination with Bretschneider-HTK solution for myocardial protection].
Many reports indicated that terminal warm blood cardioplegia (TWBC) was useful for reduction of the reperfusion injury in cardiac operations. We introduced Bretschneider-HTK solution (B-HTK) from April 1992, and combined use of the TWBC and the B-HTK was performed from May 1996. The purpose of this study was to evaluate clinical efficacy of the TWBC in combination with B-HTK for myocardial protection. In patient with valve operations from May 1995 to May 1997, clinical results were compared between the B-HTK with TWBC group (34 patients) and the B-HTK alone group (37 patients). Between two groups, there was no significant difference in patient characteristics, preoperative NYHA class, cardiopulmonary bypass time, aortic cross clamp time, minimum rectal temperature, rewarming and circulatory support time, incidence of IABP and blood concentration of max CPK, max GOT. Furthermore, the cardiac index in 1 postoperative day showed some trend to be higher in the combined TWBC group than that in the B-HTK alone group. But there was no significant difference between two groups in the LV shortening fraction at 14 postoperative day. Incidence of DC defibrillation was significantly lower in the combined TWBC group than that in the B-HTK alone group. These results suggested that combination of the TWBC might be useful for reduction of the reperfusion injury following myocardial protection with B-HTK solution.
Morishita
A
A
Department of Cardiovascular Surgery, Heart Institute of Japan, Tokyo Women's Medical University, Japan.
Kitamura
M
M
Ishitoya
H
H
Hachida
M
M
Endoh
M
M
Koyanagi
H
H
D000368:Aged; D001769:Blood; D002314:Cardioplegic Solutions / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass; D005260:Female; D005947:Glucose / Q000627:therapeutic use; D006324:Heart Arrest, Induced / Q000379:methods*; D006801:Humans; D008297:Male; D008353:Mannitol / Q000627:therapeutic use; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000628:therapy*; D011189:Potassium Chloride / Q000627:therapeutic use; D011343:Procaine / Q000627:therapeutic use
C039984:Bretschneider cardioplegic solution; D002314:Cardioplegic Solutions; D008353:Mannitol; D011343:Procaine; D011189:Potassium Chloride; D005947:Glucose